Tracing Potential Covalent Inhibitors of an E3 Ubiquitin Ligase through Target-Focused Modelling
Open accessThe DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Abstract
The Nedd4-1 E3 Ubiquitin ligase has been implicated in multiple disease conditions due its overexpression. Although the enzyme may be targeted both covalently and non-covalently, minimal studies provide effective inhibitors against it. Recently, research has focused on covalent inhibitors based on their characteristic, highly-selective warheads and ability to prevent drug resistance. This prompted us to screen for new covalent inhibitors of Nedd4-1 using a combination of computational approaches. However, this task proved challenging due to the limited number of electrophilic moieties available in virtual libraries. Therefore, we opted to divide an existing covalent Nedd4-1 inhibitor into two parts: a non-covalent binding group and a pre-selected α, β-unsaturated ester that forms the covalent linkage with the protein. A non-covalent pharmacophore model was built based on molecular interactions at the binding site. The pharmacophore was then subjected to virtual screening to identify structurally similar hit compounds. Multiple filtrations were implemented prior to selecting four hits, which were validated with a covalent conjugation and later assessed by molecular dynamic simulations. The results showed that, of the four hit molecules, Zinc00937975 exhibited advantageous molecular groups, allowing for favourable interactions with one of the characteristic cysteine residues. Predictive pharmacokinetic analysis further justified the compound as a potential lead molecule, prompting its recommendation for confirmatory biological evaluation. Our inhouse, refined, pharmacophore model approach serves as a robust method that will encourage screening for novel covalent inhibitors in drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that there is a reduced risk for the development of drug resistance against covalent drugs, which is a major challenge in areas such as oncology and infectious diseases.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [39]
In the citing paper
“Studies have indicated that covalent drugs are less likely to promote resistance [39], which could be important for diseases such as cancer and infectious diseases where drug resistance is a major challenge.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VMD: visual molecular dynamics
Humphrey, W., Dalke, A., & Schulten, K. (1996) · Journal of Molecular Graphics · doi:10.1016/0263-7855(96)00018-5 · Cited by 66,952 · cited 1×
“VMD software was used for visualizing the trajectories [25].”
MethodUCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,828 · cited 1×
“Ligand and enzyme modification as well as visualizations were performed in UCSF Chimera software package [19] and Maestro software [20].”
MethodTrott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412 · cited 1×
“The Autodock Vina tool [17] was used for all docking procedures in this study.”
MethodAutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21256 · Cited by 25,486 · cited 2×
“Although the process was run with default parameters of the software, the exhaustiveness was fixed to 8 and the grid box was defined, using AutoDock tools GUI [18], around the above-mentioned key amino acid residues of the allosteric site.”
MethodDaina, A., Michielin, O., & Zoete, V. (2017) · Scientific Reports · doi:10.1038/srep42717 · Cited by 18,367
Open Babel: An open chemical toolbox
O'Boyle, N. M., Banck, M., James, C. A., Morley, C., Vandermeersch, T., & Hutchison, G. R. (2011) · Journal of Cheminformatics · doi:10.1186/1758-2946-3-33 · Cited by 10,939 · cited 1×
“The file was downloaded and converted to MOL2 format using the Open Babel tool [15].”
MethodOn the nature of allosteric transitions: A plausible model
Monod, J., Wyman, J., & Changeux, J.-P. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80285-6 · Cited by 8,825 · cited 1×
“However, allosteric inhibition can halt substrate binding by altering one or more of the kinetic parameters that define the properties of the catalytic site and the implicated biological activity of the protein [11,12].”
BackgroundPTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data
Roe, D. R., & Cheatham, T. E. (2013) · Journal of Chemical Theory and Computation · doi:10.1021/ct400341p · Cited by 7,382
Madhavi Sastry, G., Adzhigirey, M., Day, T., Annabhimoju, R., & Sherman, W. (2013) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-013-9644-8 · Cited by 6,006 · cited 3×
“Multiple sequence alignment was then completed using the UCSF software package [20].”
MethodThe MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities
Genheden, S., & Ryde, U. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1032936 · Cited by 5,534 · cited 2×
“The MM/GBSA approach has been successfully implemented to reproduce and rationalize experimental findings as well as to expand on results obtained from virtual screening and docking calculations [31].”
MethodAutomatic atom type and bond type perception in molecular mechanical calculations
Wang, J., Wang, W., Kollman, P. A., & Case, D. A. (2006) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2005.12.005 · Cited by 5,477 · cited 1×
“Prior to the molecular dynamic (MD) simulations, the covalent ligand and the allosteric cysteine residue were parameterized to define atom types and partial charges using Antechamber module [21] in AmberTools14 suite of programs [22].”
MethodSmall-Molecule Library Screening by Docking with PyRx
Dallakyan, S., & Olson, A. J. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2269-7_19 · Cited by 3,998 · cited 3×
“Following pharmacophore-based screening, docking of the generated database (3304 compounds) was executed using the AutoDock Vina plug-in in Pyrx [16].”
MethodInfluentialHou, T., Wang, J., Li, Y., & Wang, W. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci100275a · Cited by 2,773 · cited 2×
“The relative binding free energy (ΔGbind) of compound 1, 2, 3, and 4 were computed using the Molecular Mechanics Generalized Born and Surface Area continuum solvation (MM/GBSA) approach [29].”
MethodAn overview of the Amber biomolecular simulation package
Salomon‐Ferrer, R., Case, D. A., & Walker, R. C. (2013) · WIREs Computational Molecular Science · doi:10.1002/wcms.1121 · Cited by 2,623 · cited 1×
“Prior to the molecular dynamic (MD) simulations, the covalent ligand and the allosteric cysteine residue were parameterized to define atom types and partial charges using Antechamber module [21] in AmberTools14 suite of programs [22].”
MethodInsights into Protein–Ligand Interactions: Mechanisms, Models, and Methods
Du, X., Li, Y., Xia, Y.-L., Ai, S.-M., Liang, J., Sang, P., Ji, X.-L., & Liu, S.-Q. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020144 · Cited by 1,657 · cited 2×
“M/GBSA rely on molecular simulations of the ligand-protein complex to co t i t tistical- echanical binding fr energy within a specified force field [30].”
MethodRegulation and cellular roles of ubiquitin-specific deubiquitinating enzymes.
Reyes-Turcu, F. E., Ventii, K. H., & Wilkinson, K. D. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.082307.091526 · Cited by 1,396 · cited 1×
“These enzymes play an important role in the ubiquitination process, by transferring protein substrates to ubiquitin [3,4].”
BackgroundPhysiological functions of the HECT family of ubiquitin ligases
Rotin, D., & Kumar, S. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2690 · Cited by 1,067 · cited 1×
“The main class of E3 ubiquitin ligases are enzymes that constitute a HECT (homologous to E6-AP carboxyl terminus) domain [1,2].”
BackgroundPorter, C. T. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh028 · Cited by 604 · cited 1×
“The catalytic inhibition of the enzyme blocks the substrate from binding by occupying its active site [10].”
BackgroundThe Nedd4 family of E3 ubiquitin ligases: functional diversity within a common modular architecture
Ingham, R. J., Gish, G., & Pawson, T. (2004) · Oncogene · doi:10.1038/sj.onc.1207436 · Cited by 531 · cited 1×
“In addition to the HECT region incorporated in the C-terminal domain, Nedd4-1 contains two other domains: the N-terminal domain and the multiple WW domain (double tryptophan residues) [6].”
BackgroundOriginPro 9.1: Scientific Data Analysis and Graphing Software—Software Review
Seifert, E. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500161d · Cited by 509
Nedd4 and Nedd4-2: closely related ubiquitin-protein ligases with distinct physiological functions
Yang, B., & Kumar, S. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.84 · Cited by 240 · cited 1×
“Previous studies also support our analysis; Nedd4-1 and Nedd4-2 are most phylogenetically-related and the overexpression of either enzyme may lead to dysfunctional metabolic processes [34,35].”
ResultPandey, P. K., Sharma, A. K., & Gupta, U. (2016) · Tissue Barriers · doi:10.1080/21688370.2015.1129476 · Cited by 133 · cited 1×
“This downfall may be alleviated by the encapsulation of the compounds within a drug delivery system to allow for passage [33].”
BackgroundMolecular functions of NEDD4 E3 ubiquitin ligases in cancer
Zou, X., Levy‐Cohen, G., & Blank, M. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.06.005 · Cited by 110 · cited 2×
“When overexpressed, Nedd4-1 alters normal metabolic processes, thereby implicating the enzyme in the pathogenesis of many human cancers [7,8].”
BackgroundKathman, S. G., Span, I., Smith, A. T., Xu, Z., Zhan, J., Rosenzweig, A. C., & Statsyuk, A. V. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b06839 · Cited by 104 · cited 3×
“Experimental studies as well as computational results from previous reports exhibit the selectivity of a covalent inhibitor toward the allosteric site over the binding to the catalytic site of Nedd4-1 [9,13].”
BackgroundMethodNEDD4: A Promising Target for Cancer Therapy
Ye, X., Wang, L., Shang, B., Wang, Z. P., & Wei, W. (2014) · Current Cancer Drug Targets · doi:10.2174/1568009614666140725092430 · Cited by 78 · cited 2×
“When overexpressed, Nedd4-1 alters normal metabolic processes, thereby implicating the enzyme in the pathogenesis of many human cancers [7,8].”
BackgroundPhysiological Functions of Nedd4-2: Lessons from Knockout Mouse Models
Manning, J. A., & Kumar, S. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.06.004 · Cited by 76
(2014) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2014.4119 · Cited by 68 · cited 2×
“com); hybridization state and proper angles were assessed using Molegro Molecular Viewer (MMV) [14].”
MethodInfluentialHECT Domain-containing E3 Ubiquitin Ligase Nedd4 Interacts with and Ubiquitinates Sprouty2
Edwin, F., Anderson, K. M., & Patel, T. B. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.030882 · Cited by 59 · cited 1×
“The Neural precursor cell Expressed Developmentally Down-regulated gene 4-1 (Nedd4-1) ubiquitin ligase is one of the Nedd4 enzymes that uses the HECT domain in the ubiquitination process [5].”
BackgroundAllosteric Theory: Taking Therapeutic Advantage of the Malleable Nature of GPCRs
Kenakin, T. (2007) · Current Neuropharmacology · doi:10.2174/157015907781695973 · Cited by 46 · cited 1×
“However, allosteric inhibition can halt substrate binding by altering one or more of the kinetic parameters that define the properties of the catalytic site and the implicated biological activity of the protein [11,12].”
BackgroundCrosstalk between kinases and Nedd4 family ubiquitin ligases
An, H., Krist, D. T., & Statsyuk, A. V. (2014) · Molecular BioSystems · doi:10.1039/c3mb70572b · Cited by 32
Ubiquitination without E1 and E2 enzymes
Bhogaraju, S., & Đikić, I. (2016) · Nature · doi:10.1038/nature17888 · Cited by 29
Bjij, I., Khan, S., Betz, R. M., Cherqaoui, D., & Soliman, M. E. S. (2018) · The Protein Journal · doi:10.1007/s10930-018-9795-5 · Cited by 13 · cited 4×
“Experimental studies as well as computational results from previous reports exhibit the selectivity of a covalent inhibitor toward the allosteric site over the binding to the catalytic site of Nedd4-1 [9,13].”
BackgroundMethodInfluentialSelf-citation[G3BP: a promising target for cancer therapy].
Zhang, H., & Shao, R. (2010) · PubMed · Cited by 5
Research works printed but not linked: 1
- Bethesda (MD): National Library of Medicine (US) (2018, March 11). National Center for Biotechnology Information (NCBI), Available online: https://www.ncbi.nlm.nih.gov/.
Cited by
Sabe, V. T., Ntombela, T., Jhamba, L. A., Maguire, G. E. M., Govender, T., Naicker, T., & Kruger, H. G. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113705 · Cited by 625
The design and development of covalent protein-protein interaction inhibitors for cancer treatment
Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00850-0 · Cited by 98
“Studies have indicated that covalent drugs are less likely to promote resistance [39], which could be important for diseases such as cancer and infectious diseases where drug resistance is a major challenge.”
BackgroundAdewumi, A. T., El-Rashedy, A. A. E., Soremekun, O. S., Ajadi, M. B., & Soliman, M. E. S. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1844061 · Cited by 27
“…covalent inhibition of biological targets using covalent compounds to cure pathogenic diseases has remained promising in the drug design area (Bjij et al., 2019), and the dynamic perspectives in this study corroborated with the experimental protocol reported on the putative covalent…”
Self-citationE3 Ubiquitin Ligase Regulators of Notch Receptor Endocytosis: From Flies to Humans
Revici, R., Hosseini-Alghaderi, S., Haslam, F., Whiteford, R., & Baron, M. (2022) · Biomolecules · doi:10.3390/biom12020224 · Cited by 21
“Other computational modelling and structural studies have identified and optimised agents that act through cysteine covalent modification [125,126].”
BackgroundCovalent Flexible Peptide Docking in Drug Discovery: Current Challenges and Potential Interventions
Lafifi, Z., Bjij, I., & Soliman, M. E. S. (2024) · Innovation Discovery · doi:10.53964/id.2024015 · Cited by 1
Self-citation
Metadata
- Authors
- Bjij, I., Ramharack, P., Khan, S., Cherqaoui, D., & Soliman, M. E. S.
- Affiliations
- Cadi Ayyad University (MA)
- University of KwaZulu-Natal (ZA)
- University of the Witwatersrand (ZA)
- Corresponding author
- Soliman, Mahmoud E. S.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2019-08-28
- Volume
- 24
- Issue
- 17
- Pages
- 3125
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC6749425
- OpenAlex
- W2970088476
- Cited by
- 6
- References
- 35
- Citations by year
- 2026: 1 · 2024: 1 · 2022: 1 · 2021: 1 · 2020: 2
- FWCI
- 0.68
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- College of Health Sciences, University of KwaZulu-Natal (N/A)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and Characterization of Heterocyclic Compounds
- Keywords
- NEDD4-1, E3 ubiquitin ligase, covalent inhibitors, pharmacophore modeling, virtual screening, α,β-unsaturated esters, electrophilic warheads, cysteine residues, drug resistance, molecular dynamics simulation
- MeSH terms
- Binding Sites, Computer Simulation, Cysteine, Enzyme Inhibitors, Humans, Hydrogen Bonding, Models, Molecular, Structure-Activity Relationship, Molecular Structure, Ubiquitin-Protein Ligases, Drug Discovery, Molecular Dynamics Simulation, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.